HYDELTRASOL (prednisolone sodium phosphate) by Merck & Co. is clinical pharmacology naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Approved for multiple sclerosis.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
HYDELTRASOL (Prednisolone Sodium Phosphate) is a synthetic glucocorticoid administered via injection for rapid anti-inflammatory and immunosuppressive effects. It is indicated for Multiple Sclerosis and works by inhibiting inflammatory processes, suppressing immune cell production, and modulating glucocorticoid-mediated physiological responses. The injectable formulation produces 14% higher peak plasma levels 20% faster than oral tablets, enabling acute therapeutic intervention.
As a pre-launch product from Merck & Co., this represents a new market entry opportunity with significant team-building potential across commercial, medical affairs, and manufacturing functions.
CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many…
Worked on HYDELTRASOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moHYDELTRASOL represents a pre-launch, established-mechanism product opportunity within Merck's neurology portfolio. Career roles will emphasize commercial execution, payer education on parenteral delivery advantages, and physician adoption in a competitive DMT-dominated market rather than novel science development.